Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers

R. C. Wood, K. L. MacDonald, K. E. White, C. W. Hedberg, M. Hanson and M. T. Osterholm
Acute Disease Epidemiology Section, Minnesota Department of Health, Minneapolis 55440-9441.

OBJECTIVE--To assess the presence of antibody to hepatitis B surface antigen (anti-HBs) at postvaccination testing in Minnesota health care workers receiving recombinant hepatitis B vaccines, and to identify risk factors for lacking anti-HBs following hepatitis B vaccination. DESIGN--Retrospective cohort study. SETTING--Ten acute care hospitals in Minnesota. PARTICIPANTS--A total of 595 health care workers who had received hepatitis B vaccine (Recombivax HB or Engerix-B) between June 1987 and December 1991 and who underwent postvaccination testing for anti-HBs within 6 months after receiving the third dose of vaccine. MAIN OUTCOME MEASURE--Presence or absence of anti-HBs following hepatitis B vaccination. RESULTS--Five variables were independently associated with lacking anti-HBs by multivariate analysis: vaccine brand, smoking status, gender, age, and body mass index. Stratifying by vaccine brand demonstrated that age (P = .01), body mass index (P < .01), and smoking status (P < .01) were associated with lacking anti-HBs only for Recombivax HB recipients; and gender (P = .03) was associated with lacking anti-HBs only for Engerix-B recipients. After controlling for smoking status, age, gender, and body mass index, recipients of Recombivax HB were more likely to lack anti-HBs than recipients of Engerix-B (relative risk, 2.3; 95% confidence interval, 1.1 to 4.7; P = .02). CONCLUSIONS--Results indicate that certain populations of health care workers are at increased risk of not responding to hepatitis B vaccination. Further studies evaluating immunogenicity of currently available recombinant hepatitis B vaccines in persons at high risk for primary vaccine failure are needed.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hepatitis B in Moroccan health care workers
Djeriri et al.
Occup Med (Lond) 2008;58:419-424.
ABSTRACT | FULL TEXT  

Gluten Intake Interferes With the Humoral Immune Response to Recombinant Hepatitis B Vaccine in Patients With Celiac Disease
Nemes et al.
Pediatrics 2008;121:e1570-e1576.
ABSTRACT | FULL TEXT  

Hepatitis vaccines
Karayiannis et al.
Br Med Bull 2004;70:29-49.
FULL TEXT  

Post-exposure prophylaxis for blood borne viral infections in healthcare workers
Varghese et al.
Postgrad. Med. J. 2003;79:324-328.
ABSTRACT | FULL TEXT  

Update on chronic viral hepatitis
Walsh and Alexander
Postgrad. Med. J. 2001;77:498-505.
ABSTRACT | FULL TEXT  

Serologic Hepatitis B Immunity in Vaccinated Health Care Workers
Barash et al.
Arch Intern Med 1999;159:1481-1483.
ABSTRACT | FULL TEXT  

Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection
Mahoney
Clin. Microbiol. Rev. 1999;12:351-366.
ABSTRACT | FULL TEXT  

Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study
Zuckerman et al.
BMJ 1997;314:329-329.
ABSTRACT | FULL TEXT  

Vaccines to Prevent Viral Hepatitis
Lemon and Thomas
NEJM 1997;336:196-204.
FULL TEXT  

Evaluation of Needle Length and Hepatitis B Vaccine Response in Correctional Personnel in Massachusetts
Johnsen
JOURNAL OF CORRECTIONAL HEALTH CARE 1995;2:39-45.
ABSTRACT  

Management of Occupational Exposures to Blood-Borne Viruses
Gerberding
NEJM 1995;332:444-451.
FULL TEXT  

PREDICTORS OF POOR RESPONSE TO HEPATITIS B VACCINE
JWatch General 1994;1994:3-3.
FULL TEXT